福瑞股份(300049.SZ):2021年度淨利預增45.38%-69.61%
格隆匯1月14日丨福瑞股份(300049.SZ)披露2021年度業績預吿,預計2021年度實現歸屬於上市公司股東的淨利潤0.90億元-1.05億元,同比增長45.38%-69.61%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤0.85億元-1.00億元,同比增長4.71%-46.72%。
報吿期內,業績變動的主要原因為:1、因公司藥品業務銷售模式的轉變,該年度藥品業務的銷售收入和淨利潤較上年實現增長;2、由於新冠肺炎疫情的影響較上年減弱,該年度公司醫療器械的全球業務銷售收入和淨利潤較上年實現增長;3、2021年度,公司實施了員工持股計劃,該年度需攤銷股份支付費用約1670萬元;4、2021年度,非經常性損益對淨利潤的影響金額預計為不超過500萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.